Evidence map›Paper›PMID 33836616›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Loss of expression of both miR-15/16 loci in CML transition to blast crisis.

Francesca Lovat, Pierluigi Gasparini, Giovanni Nigita, Karilyn Larkin, John C Byrd, Mark D Minden, Michael Andreeff, Bing Z Carter, Carlo M Croce

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Complete miRNA-15/16 loss in mice promotes hematopoietic progenitor expansion and a myeloid-biased hyperproliferative state.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Article
  5. Review
  6. Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?International journal of molecular sciences · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Francesca LovatDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Pierluigi GaspariniDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Giovanni NigitaDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210.
Karilyn LarkinComprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-1898-9836
John C ByrdComprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Mark D MindenDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-9089-8816
Michael AndreeffSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-1144-1958
Bing Z CarterSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-0076-0889
Carlo M CroceDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210; carlo.croce@osumc.edu.ORCID 0000-0003-3788-1457
The Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CA

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
NCI NIH HHS P30 CA016058NCI NIH HHS R35 CA197706
6 · The paper itself

Abstract

Despite advances that have improved the treatment of chronic myeloid leukemia (CML) patients in chronic phase, the mechanisms of the transition from chronic phase CML to blast crisis (BC) are not fully understood. Considering the key role of miR-15/16 loci in the pathogenesis of myeloid and lymphocytic leukemia, here we aimed to correlate the expression of miR-15a/16 and miR-15b/16 to progression of CML from chronic phase to BC. We analyzed the expression of the two miR-15/16 clusters in 17 CML patients in chronic phase and 22 patients in BC and in 11 paired chronic phase and BC CML patients. BC CMLs show a significant reduction of the expression of miR-15a/-15b/16 compared to CMLs in chronic phase. Moreover, BC CMLs showed an overexpression of miR-15/16 direct targets such as Bmi-1, ROR1, and Bcl-2 compared to CMLs in chronic phase. This study highlights the loss of both miR-15/16 clusters as a potential oncogenic driver in the transition from chronic phase to BC in CML patients.

Indexed as

AdultBlast CrisisDisease ProgressionFemaleGene Expression Regulation, LeukemicGenetic LociHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMicroRNAsMiddle AgedPolycomb Repressive Complex 1Proto-Oncogene Proteins c-bcl-2Receptor Tyrosine Kinase-like Orphan ReceptorsBCL2 protein, humanBMI1 protein, humanMicroRNAsMIRN15 microRNA, humanMIRN16 microRNA, humanPolycomb Repressive Complex 1Proto-Oncogene Proteins c-bcl-2Receptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanblast crisischronic myeloid leukemiamiR-15/16 cluster

Identifiers

PMID33836616
PMCPMC7980455
OpenAlexW3134528205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.